Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Summary

The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint blockade. Based on these reasons, the investigators planned a phase II study of durvalumab monotherapy in patients with previously treated, metastatic, MMR deficient (MSI-H) or POLE mutated colorectal cancer.

Timeline

Start

2018-04-12

Primary completion

2023-04-26

Completion

2023-04-26

Drugs

Indications